{
  "trial_id": "NCT00606008",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Resolution of all acute toxic effects of prior chemotherapy or radiotherapy or surgical procedures to NCI CTCAE Version 3.0 grade \u22641.",
      "label": "met"
    },
    {
      "criterion": "Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) \u22643 x local laboratory upper limit of normal (ULN), or AST and ALT \u22643 x ULN if liver function abnormalities are due to underlying malignancy.",
      "label": "met"
    },
    {
      "criterion": "Total serum bilirubin \u22641.5 x ULN",
      "label": "met"
    },
    {
      "criterion": "Absolute neutrophil count (ANC) \u22651500/\u00b5L",
      "label": "met"
    },
    {
      "criterion": "Platelets \u2265100,000/\u00b5L",
      "label": "met"
    },
    {
      "criterion": "Hemoglobin \u22659.0 g/dL",
      "label": "met"
    },
    {
      "criterion": "Serum calcium \u226412.0 mg/dL",
      "label": "met"
    },
    {
      "criterion": "Serum creatinine \u22641.5 x ULN",
      "label": "met"
    },
    {
      "criterion": "Patients must have histologically or neuroradiographically recurrent anaplastic astrocytoma (AA) or glioblastoma (GBM). Must have had prior pathologic confirmation of primary tumor histology.",
      "label": "met"
    },
    {
      "criterion": "Must be \u2265 18 years old.",
      "label": "met"
    },
    {
      "criterion": "Must have a Karnofsky performance status (KPS) \u2265 60%",
      "label": "met"
    },
    {
      "criterion": "Measurable disease per MacDonald criteria required using contrast enhanced cranial MRI.",
      "label": "met"
    },
    {
      "criterion": "Life expectancy \u2265 12 weeks.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Major surgery or radiation therapy within 4 weeks of starting study treatment.",
      "label": "not_met"
    },
    {
      "criterion": "NCI CTCAE grade 3 hemorrhage within 4 weeks of starting study treatment.",
      "label": "unknown"
    },
    {
      "criterion": "History of or known spinal cord compression or carcinomatous meningitis, or evidence of leptomeningeal disease on screening CT or MRI scan.",
      "label": "not_met"
    }
  ],
  "notes": "Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT00606008",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}